Anemia and iron deficiency in cancer patients: Role of iron replacement therapy

Pharmaceuticals

Volumn 11, Issue 4, 2018, Pages

  Busti, Fabiana ^a   Marchi, Giacomo ^a   Ugolini, Sara ^a   Castagna, Annalisa ^a   Girelli, Domenico ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Anemia; Cancer; Hepcidin; Iron deficiency; Patient blood management

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADVERSE OUTCOME; ANEMIA; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CARCINOMA; COMORBIDITY; ERYTHROPHAGOCYTOSIS; FERRITIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPERSPLENISM; IRON DEFICIENCY; IRON METABOLISM; IRON THERAPY; MALNUTRITION; MORTALITY RISK; PATHOGENESIS; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PREVALENCE; QUALITY OF LIFE; RETICULOCYTE HEMOGLOBIN CONTENT; REVIEW;

EID: 85055752234     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph11040094     Document Type: Review

References (103)

1. Ludwig, H.; Van Belle, S.; Barrett-Lee, P.; Birgegard, G.; Bokemeyer, C.; Gascon, P.; Kosmidis, P.; Krzakowski, M.; Nortier, J.; Olmi, P.; et al. The European cancer anaemia survey (ecas): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 2004, 40, 2293-2306. [CrossRef] [PubMed]
2. National Comprehensive Cancer Network. Available online: http://www.nccn.org/professionals/physici an_gls/PDF/anemia.pdf (accessed on 27 August 2018).
3. Knight, K.; Wade, S.; Balducci, L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am. J. Med. 2004, 116, 11S-26S. [CrossRef] [PubMed]
4. Grotto, H.Z. Anaemia of cancer: An overview of mechanisms involved in its pathogenesis. Med. Oncol. 2008, 25, 12-21. [CrossRef] [PubMed]
5. Gilreath, J.A.; Stenehjem, D.D.; Rodgers, G.M. Diagnosis and treatment of cancer-related anemia. Am. J. Hematol. 2014, 89, 203-212. [CrossRef] [PubMed]
6. Gaspar, B.L.; Sharma, P.; Das, R. Anemia in malignancies: Pathogenetic and diagnostic considerations. Hematology 2015, 20, 18-25. [CrossRef] [PubMed]
7. Adamson, J.W. The anemia of inflammation/malignancy: Mechanisms and management. Hematol. Am. Soc. Hematol. Educ. Program 2008, 2008, 159-165. [CrossRef] [PubMed]
8. van Eeden, R.; Rapoport, B.L. Current trends in the management of anaemia in solid tumours and haematological malignancies. Curr. Opin. Support Palliat. Care 2016, 10, 189-194. [CrossRef] [PubMed]
9. Harper, P.; Littlewood, T. Anaemia of cancer: Impact on patient fatigue and long-term outcome. Oncology 2005, 69, 2-7. [CrossRef] [PubMed]
10. Crawford, J.; Cella, D.; Cleeland, C.S.; Cremieux, P.Y.; Demetri, G.D.; Sarokhan, B.J.; Slavin, M.B.; Glaspy, J.A. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002, 95, 888-895. [CrossRef] [PubMed]
11. Caro, J.J.; Salas, M.; Ward, A.; Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001, 91, 2214-2221. [CrossRef]
12. Schito, L.; Semenza, G.L. Hypoxia-inducible factors: Master regulators of cancer progression. Trends Cancer 2016, 2, 758-770. [CrossRef] [PubMed]
13. Deeb, G.; Vaughan, M.M.; McInnis, I.; Ford, L.A.; Sait, S.N.; Starostik, P.; Wetzler, M.; Mashtare, T.; Wang, E.S. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk. Res. 2011, 35, 579-584. [CrossRef] [PubMed]
14. Morine, Y.; Shimada, M.; Utsunomiya, T.; Imura, S.; Ikemoto, T.; Mori, H.; Hanaoka, J.; Kanamoto, M.; Iwahashi, S.; Miyake, H. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2011, 58, 1439-1444. [CrossRef] [PubMed]
15. Zheng, S.S.; Chen, X.H.; Yin, X.; Zhang, B.H. Prognostic significance of hif-1alpha expression in hepatocellular carcinoma: A meta-analysis. PLoS ONE 2013, 8, e65753.
16. Semenza, G.L. Hif-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol. Med. 2002, 8, S62-S67. [CrossRef]
17. Harrison, L.B.; Chadha, M.; Hill, R.J.; Hu, K.; Shasha, D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7, 492-508. [CrossRef] [PubMed]
18. Vaupel, P.; Harrison, L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9, 4-9. [CrossRef] [PubMed]
19. Cella, D.; Dobrez, D.; Glaspy, J. Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Ann. Oncol. 2003, 14, 511-519. [CrossRef] [PubMed]
20. Calabrich, A.; Katz, A. Management of anemia in cancer patients. Future Oncol. 2011, 7, 507-517. [CrossRef] [PubMed]
21. Littlewood, T.J.; Bajetta, E.; Nortier, J.W.; Vercammen, E.; Rapoport, B.; Epoetin Alfa Study, G. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2001, 19, 2865-2874. [CrossRef] [PubMed]
22. Cata, J.P.; Wang, H.; Gottumukkala, V.; Reuben, J.; Sessler, D.I. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br. J. Anaesth. 2013, 110, 690-701. [CrossRef] [PubMed]
23. Acheson, A.G.; Brookes, M.J.; Spahn, D.R. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: A systematic review and meta-analysis. Ann. Surg. 2012, 256, 235-244. [CrossRef] [PubMed]
24. Liu, L.; Wang, Z.; Jiang, S.; Shao, B.; Liu, J.; Zhang, S.; Zhou, Y.; Zhou, Y.; Zhang, Y. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: A meta-analysis. PLoS ONE 2013, 8, e64261. [CrossRef] [PubMed]
25. Luan, H.; Ye, F.; Wu, L.; Zhou, Y.; Jiang, J. Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: A systematic review and a meta-analysis. BMC Surg. 2014, 14, 34. [CrossRef] [PubMed]
26. Sun, C.; Wang, Y.; Yao, H.S.; Hu, Z.Q. Allogeneic blood transfusion and the prognosis of gastric cancer patients: Systematic review and meta-analysis. Int. J. Surg. 2015, 13, 102-110. [CrossRef] [PubMed]
27. Prescott, L.S.; Taylor, J.S.; Lopez-Olivo, M.A.; Munsell, M.F.; VonVille, H.M.; Lairson, D.R.; Bodurka, D.C. How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology. Cancer Treat Rev. 2016, 46, 1-8. [CrossRef] [PubMed]
28. Boone, J.D.; Kim, K.H.; Marques, M.; Straughn, J.M. Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients. Gynecol. Oncol. 2014, 132, 227-230. [CrossRef] [PubMed]
29. Alkhalid, Y.; Lagman, C.; Sheppard, J.P.; Nguyen, T.; Prashant, G.N.; Ziman, A.F.; Yang, I. Restrictive transfusion threshold is safe in high-risk patients undergoing brain tumor surgery. Clin. Neurol. Neurosurg. 2017, 163, 103-107. [CrossRef] [PubMed]
30. de Almeida, J.P.; Vincent, J.L.; Galas, F.R.; de Almeida, E.P.; Fukushima, J.T.; Osawa, E.A.; Bergamin, F.; Park, C.L.; Nakamura, R.E.; Fonseca, S.M.; et al. Transfusion requirements in surgical oncology patients: A prospective, randomized controlled trial. Anesthesiology 2015, 122, 29-38. [CrossRef] [PubMed]
31. Vansteenkiste, J.; Poulsen, E.; Rossi, G.; Glaspy, J. Darbepoetin alfa: Impact on treatment for chemotherapy-induced anemia and considerations in special populations. Oncology 2002, 16, 45-55. [PubMed]
32. Hedenus, M.; Adriansson, M.; San Miguel, J.; Kramer, M.H.; Schipperus, M.R.; Juvonen, E.; Taylor, K.; Belch, A.; Altes, A.; Martinelli, G.; et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br. J. Haematol. 2003, 122, 394-403. [CrossRef] [PubMed]
33. Bennett, C.L.; Silver, S.M.; Djulbegovic, B.; Samaras, A.T.; Blau, C.A.; Gleason, K.J.; Barnato, S.E.; Elverman, K.M.; Courtney, D.M.; McKoy, J.M.; et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299, 914-924. [CrossRef] [PubMed]
34. Samaras, A.T.; Bennett, C.L. Risks of venous thromboembolism and mortality associated with erythropoiesis-stimulating agents for the treatment of cancer-associated anemia. Am. J. Hematol. Oncol. 2008, 7, 327-332. [PubMed]
35. Henke, M.; Laszig, R.; Rube, C.; Schafer, U.; Haase, K.D.; Schilcher, B.; Mose, S.; Beer, K.T.; Burger, U.; Dougherty, C.; et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003, 362, 1255-1260. [CrossRef]
36. Wright, J.R.; Ung, Y.C.; Julian, J.A.; Pritchard, K.I.; Whelan, T.J.; Smith, C.; Szechtman, B.; Roa, W.; Mulroy, L.; Rudinskas, L.; et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 2007, 25, 1027-1032. [CrossRef] [PubMed]
37. Smith, R.E., Jr.; Aapro, M.S.; Ludwig, H.; Pinter, T.; Smakal, M.; Ciuleanu, T.E.; Chen, L.; Lillie, T.; Glaspy, J.A. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 2008, 26, 1040-1050. [CrossRef] [PubMed]
38. Farrell, F.; Lee, A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004, 9, 18-30. [CrossRef] [PubMed]
39. Aapro, M.; Jelkmann, W.; Constantinescu, S.N.; Leyland-Jones, B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br. J. Cancer 2012, 106, 1249-1258. [CrossRef] [PubMed]
40. Aapro, M.; Moebus, V.; Nitz, U.; O’Shaughnessy, J.; Pronzato, P.; Untch, M.; Tomita, D.; Bohac, C.; Leyland-Jones, B. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: A meta-analysis. Ann. Oncol. 2015, 26, 688-695. [CrossRef] [PubMed]
41. Bennett, C.L.; Lai, S.Y.; Sartor, O.; Georgantopoulos, P.; Hrushesky, W.J.; Henke, M.; Armitage, J.O. Consensus on the existence of functional erythropoietin receptors on cancer cells. JAMA Oncol. 2016, 2, 134-136. [CrossRef] [PubMed]
42. Glaspy, J.; Crawford, J.; Vansteenkiste, J.; Henry, D.; Rao, S.; Bowers, P.; Berlin, J.A.; Tomita, D.; Bridges, K.; Ludwig, H. Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 2010, 102, 301-315. [CrossRef] [PubMed]
43. Ohashi, Y.; Uemura, Y.; Fujisaka, Y.; Sugiyama, T.; Ohmatsu, H.; Katsumata, N.; Okamoto, R.; Saijo, N.; Hotta, T. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from japanese randomized, placebo-controlled trials. Cancer Sci. 2013, 104, 481-485. [CrossRef] [PubMed]
44. Rizzo, J.D.; Brouwers, M.; Hurley, P.; Seidenfeld, J.; Arcasoy, M.O.; Spivak, J.L.; Bennett, C.L.; Bohlius, J.; Evanchuk, D.; Goode, M.J.; et al. American society of hematology/american society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010, 116, 4045-4059. [CrossRef] [PubMed]
45. Ludwig, H.; Muldur, E.; Endler, G.; Hubl, W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann. Oncol. 2013, 24, 1886-1892. [CrossRef] [PubMed]
46. Aapro, M.; Osterborg, A.; Gascon, P.; Ludwig, H.; Beguin, Y. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.V. Iron. Ann. Oncol. 2012, 23, 1954-1962. [CrossRef] [PubMed]
47. Ludwig, H.; Evstatiev, R.; Kornek, G.; Aapro, M.; Bauernhofer, T.; Buxhofer-Ausch, V.; Fridrik, M.; Geissler, D.; Geissler, K.; Gisslinger, H.; et al. Iron metabolism and iron supplementation in cancer patients. Wien. Klin. Wochenschr. 2015, 127, 907-919. [CrossRef] [PubMed]
48. Nemeth, E.; Rivera, S.; Gabayan, V.; Keller, C.; Taudorf, S.; Pedersen, B.K.; Ganz, T. Il-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 2004, 113, 1271-1276. [CrossRef] [PubMed]
49. Ganz, T.; Nemeth, E. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 2015, 15, 500-510. [CrossRef] [PubMed]
50. Goodnough, L.T.; Nemeth, E.; Ganz, T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010, 116, 4754-4761. [CrossRef] [PubMed]
51. Weiss, G.; Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352, 1011-1023. [CrossRef] [PubMed]
52. Ueda, N.; Takasawa, K. Role of hepcidin-25 in chronic kidney disease: Anemia and beyond. Curr. Med. Chem. 2017, 24, 1417-1452. [CrossRef] [PubMed]
53. Ueda, N.; Takasawa, K. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients 2018, 10, 1173. [CrossRef] [PubMed]
54. Aapro, M.; Beguin, Y.; Bokemeyer, C.; Dicato, M.; Gascon, P.; Glaspy, J.; Hofmann, A.; Link, H.; Littlewood, T.; Ludwig, H.; et al. Management of anaemia and iron deficiency in patients with cancer: Esmo clinical practice guidelines. Ann. Oncol. 2018. [CrossRef]
55. Anand, I.S.; Gupta, P. Anemia and iron deficiency in heart failure: Current concepts and emerging therapies. Circulation 2018, 138, 80-98. [CrossRef] [PubMed]
56. Steinmetz, T.; Tschechne, B.; Harlin, O.; Klement, B.; Franzem, M.; Wamhoff, J.; Tesch, H.; Rohrberg, R.; Marschner, N. Clinical experience with ferric carboxymaltose in the treatment of cancer-and chemotherapy-associated anaemia. Ann. Oncol. 2013, 24, 475-482. [CrossRef] [PubMed]
57. Verhaeghe, L.; Bruyneel, L.; Stragier, E.; Ferrante, M.; Dierickx, D.; Prenen, H. The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: A retrospective study. Ann. Gastroenterol. 2017, 30, 654-663. [CrossRef] [PubMed]
58. Cappellini, M.D.; Comin-Colet, J.; de Francisco, A.; Dignass, A.; Doehner, W.; Lam, C.S.; Macdougall, I.C.; Rogler, G.; Camaschella, C.; Kadir, R.; et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am. J. Hematol. 2017, 92, 1068-1078. [CrossRef] [PubMed]
59. Pfeiffer, C.M.; Looker, A.C. Laboratory methodologies for indicators of iron status: Strengths, limitations, and analytical challenges. Am. J. Clin. Nutr. 2017, 106, 1606S-1614S. [CrossRef] [PubMed]
60. Girelli, D.; Nemeth, E.; Swinkels, D.W. Hepcidin in the diagnosis of iron disorders. Blood 2016, 127, 2809-2813. [CrossRef] [PubMed]
61. Theurl, I.; Aigner, E.; Theurl, M.; Nairz, M.; Seifert, M.; Schroll, A.; Sonnweber, T.; Eberwein, L.; Witcher, D.R.; Murphy, A.T.; et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications. Blood 2009, 113, 5277-5286. [CrossRef] [PubMed]
62. van Santen, S.; van Dongen-Lases, E.C.; de Vegt, F.; Laarakkers, C.M.; van Riel, P.L.; van Ede, A.E.; Swinkels, D.W. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011, 63, 3672-3680. [CrossRef] [PubMed]
63. Bergamaschi, G.; Di Sabatino, A.; Albertini, R.; Costanzo, F.; Guerci, M.; Masotti, M.; Pasini, A.; Massari, A.; Campostrini, N.; Corbella, M.; et al. Serum hepcidin in inflammatory bowel diseases: Biological and clinical significance. Inflamm. Bowel Dis. 2013, 19, 2166-2172. [CrossRef] [PubMed]
64. Shu, T.; Jing, C.; Lv, Z.; Xie, Y.; Xu, J.; Wu, J. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: Pathogenic mechanisms and diagnosis. Eur. J. Haematol. 2015, 94, 67-73. [CrossRef] [PubMed]
65. Prentice, A.M.; Doherty, C.P.; Abrams, S.A.; Cox, S.E.; Atkinson, S.H.; Verhoef, H.; Armitage, A.E.; Drakesmith, H. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012, 119, 1922-1928. [CrossRef] [PubMed]
66. Steensma, D.P.; Sasu, B.J.; Sloan, J.A.; Tomita, D.K.; Loprinzi, C.L. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood 2015, 125, 3669-3671. [CrossRef] [PubMed]
67. van der Vorm, L.N.; Hendriks, J.C.; Laarakkers, C.M.; Klaver, S.; Armitage, A.E.; Bamberg, A.; Geurts-Moespot, A.J.; Girelli, D.; Herkert, M.; Itkonen, O.; et al. Toward worldwide hepcidin assay harmonization: Identification of a commutable secondary reference material. Clin. Chem. 2016, 62, 993-1001. [CrossRef] [PubMed]
68. Auerbach, M.; Ballard, H.; Trout, J.R.; McIlwain, M.; Ackerman, A.; Bahrain, H.; Balan, S.; Barker, L.; Rana, J. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J. Clin. Oncol. 2004, 22, 1301-1307. [CrossRef] [PubMed]
69. Hedenus, M.; Birgegard, G.; Nasman, P.; Ahlberg, L.; Karlsson, T.; Lauri, B.; Lundin, J.; Larfars, G.; Osterborg, A. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007, 21, 627-632. [CrossRef] [PubMed]
70. Henry, D.H. Epoetin alfa treatment for patients with chemotherapy-induced anemia. Support Cancer Ther. 2007, 4, 78-91. [CrossRef] [PubMed]
71. Bastit, L.; Vandebroek, A.; Altintas, S.; Gaede, B.; Pinter, T.; Suto, T.S.; Mossman, T.W.; Smith, K.E.; Vansteenkiste, J.F. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 2008, 26, 1611-1618. [CrossRef] [PubMed]
72. Pedrazzoli, P.; Farris, A.; Del Prete, S.; Del Gaizo, F.; Ferrari, D.; Bianchessi, C.; Colucci, G.; Desogus, A.; Gamucci, T.; Pappalardo, A.; et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J. Clin. Oncol. 2008, 26, 1619-1625. [CrossRef] [PubMed]
73. Auerbach, M.; Silberstein, P.T.; Webb, R.T.; Averyanova, S.; Ciuleanu, T.E.; Shao, J.; Bridges, K. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am. J. Hematol. 2010, 85, 655-663. [CrossRef] [PubMed]
74. Mhaskar, R.; Wao, H.; Miladinovic, B.; Kumar, A.; Djulbegovic, B. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst. Rev. 2016, 2, CD009624. [CrossRef] [PubMed]
75. Gafter-Gvili, A.; Rozen-Zvi, B.; Vidal, L.; Leibovici, L.; Vansteenkiste, J.; Gafter, U.; Shpilberg, O. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—Systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013, 52, 18-29. [CrossRef] [PubMed]
76. Petrelli, F.; Borgonovo, K.; Cabiddu, M.; Lonati, V.; Barni, S. Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials. J. Cancer Res. Clin. Oncol. 2012, 138, 179-187. [CrossRef] [PubMed]
77. Girelli, D.; Ugolini, S.; Busti, F.; Marchi, G.; Castagna, A. Modern iron replacement therapy: Clinical and pathophysiological insights. Int. J. Hematol. 2018, 107, 16-30. [CrossRef] [PubMed]
78. Kim, Y.T.; Kim, S.W.; Yoon, B.S.; Cho, H.J.; Nahm, E.J.; Kim, S.H.; Kim, J.H.; Kim, J.W. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol. Oncol. 2007, 105, 199-204. [CrossRef] [PubMed]
79. Dangsuwan, P.; Manchana, T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol. Oncol. 2010, 116, 522-525. [CrossRef] [PubMed]
80. Athibovonsuk, P.; Manchana, T.; Sirisabya, N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol. Oncol. 2013, 131, 679-682. [CrossRef] [PubMed]
81. Hedenus, M.; Karlsson, T.; Ludwig, H.; Rzychon, B.; Felder, M.; Roubert, B.; Birgegard, G. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med. Oncol. 2014, 31, 302. [CrossRef] [PubMed]
82. Coussirou, J.; Debourdeau, A.; Stancu, A.; Jean, C.; Azouza, W.; Chanet, B.; De Crozals, F.; Boustany, R.; Debourdeau, P. Impact of ferric carboxymaltose on the evolution of hemoglobin and ecog performance status in iron-deficient patients with solid tumors: A 3-month follow-up retrospective study. Support Care Cancer 2018, 26, 3827-3834. [CrossRef] [PubMed]
83. Clevenger, B.; Mallett, S.V.; Klein, A.A.; Richards, T. Patient blood management to reduce surgical risk. Br. J. Surg. 2015, 102, 1325-1337. [CrossRef] [PubMed]
84. Munoz, M.; Gomez-Ramirez, S.; Campos, A.; Ruiz, J.; Liumbruno, G.M. Pre-operative anaemia: Prevalence, consequences and approaches to management. Blood Transfus. 2015, 13, 370-379. [PubMed]
85. Rineau, E.; Chaudet, A.; Chassier, C.; Bizot, P.; Lasocki, S. Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: A before-after study. Transfusion 2016, 56, 673-681. [CrossRef] [PubMed]
86. Yoo, Y.C.; Shim, J.K.; Kim, J.C.; Jo, Y.Y.; Lee, J.H.; Kwak, Y.L. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011, 115, 929-937. [CrossRef] [PubMed]
87. Ecker, B.L.; Simmons, K.D.; Zaheer, S.; Poe, S.L.; Bartlett, E.K.; Drebin, J.A.; Fraker, D.L.; Kelz, R.R.; Roses, R.E.; Karakousis, G.C. Blood transfusion in major abdominal surgery for malignant tumors: A trend analysis using the national surgical quality improvement program. JAMA Surg. 2016, 151, 518-525. [CrossRef] [PubMed]
88. Dixon, E.; Datta, I.; Sutherland, F.R.; Vauthey, J.N. Blood loss in surgical oncology: Neglected quality indicator? J. Surg. Oncol. 2009, 99, 508-512. [CrossRef] [PubMed]
89. Keding, V.; Zacharowski, K.; Bechstein, W.O.; Meybohm, P.; Schnitzbauer, A.A. Patient blood management improves outcome in oncologic surgery. World J. Surg. Oncol. 2018, 16, 159. [CrossRef] [PubMed]
90. Borstlap, W.A.; Stellingwerf, M.E.; Moolla, Z.; Musters, G.D.; Buskens, C.J.; Tanis, P.J.; Bemelman, W.A. Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma: A systematic review. Colorectal Dis. 2015, 17, 1044-1054. [CrossRef] [PubMed]
91. Keeler, B.D.; Simpson, J.A.; Ng, S.; Tselepis, C.; Iqbal, T.; Brookes, M.J.; Acheson, A.G. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Colorectal Dis. 2014, 16, 794-800. [CrossRef] [PubMed]
92. Edwards, T.J.; Noble, E.J.; Durran, A.; Mellor, N.; Hosie, K.B. Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br. J. Surg. 2009, 96, 1122-1128. [CrossRef] [PubMed]
93. Lidder, P.G.; Sanders, G.; Whitehead, E.; Douie, W.J.; Mellor, N.; Lewis, S.J.; Hosie, K.B. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery—A prospective, randomised, controlled trial. Ann. R. Coll. Surg. Engl. 2007, 89, 418-421. [CrossRef] [PubMed]
94. Calleja, J.L.; Delgado, S.; del Val, A.; Hervas, A.; Larraona, J.L.; Teran, A.; Cucala, M.; Mearin, F.; Colon Cancer Study, G. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int. J. Colorectal Dis. 2016, 31, 543-551. [CrossRef] [PubMed]
95. Froessler, B.; Palm, P.; Weber, I.; Hodyl, N.A.; Singh, R.; Murphy, E.M. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: A randomized controlled trial. Ann. Surg. 2016, 264, 41-46. [CrossRef] [PubMed]
96. Torti, S.V.; Torti, F.M. Iron and cancer: More ore to be mined. Nat. Rev. Cancer 2013, 13, 342-355. [CrossRef] [PubMed]
97. Manz, D.H.; Blanchette, N.L.; Paul, B.T.; Torti, F.M.; Torti, S.V. Iron and cancer: Recent insights. Ann. N. Y. Acad. Sci. 2016, 1368, 149-161. [CrossRef] [PubMed]
98. Gilreath, J.A.; Stenehjem, D.D.; Rodgers, G.M. Total dose iron dextran infusion in cancer patients: Is it safe2+? J. Natl. Compr. Cancer Netw. 2012, 10, 669-676. [CrossRef]
99. Beguin, Y.; Aapro, M.; Ludwig, H.; Mizzen, L.; Osterborg, A. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis—A critical review. Crit. Rev. Oncol. Hematol. 2014, 89, 1-15. [CrossRef] [PubMed]
100. Jaspers, A.; Baron, F.; Servais, S.; Lejeune, M.; Willems, E.; Seidel, L.; Hafraoui, K.; Bonnet, C.; Beguin, Y. Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival. Am. J. Hematol. 2015, 90, E197-E199. [CrossRef] [PubMed]
101. Wilson, M.J.; Dekker, J.W.T.; Buettner, S.; Harlaar, J.J.; Jeekel, J.; Schipperus, M.; Zwaginga, J.J. The effect of intravenous iron therapy on long-term survival in anaemic colorectal cancer patients: Results from a matched cohort study. Surg. Oncol. 2018, 27, 192-199. [CrossRef] [PubMed]
102. Nairz, M.; Dichtl, S.; Schroll, A.; Haschka, D.; Tymoszuk, P.; Theurl, I.; Weiss, G. Iron and innate antimicrobial immunity-depriving the pathogen, defending the host. J. Trace Elem. Med. Biol. 2018, 48, 118-133. [CrossRef] [PubMed]
103. Busti, F.; Campostrini, N.; Martinelli, N.; Girelli, D. Iron deficiency in the elderly population, revisited in the hepcidin era. Front. Pharmacol. 2014, 5, 83. [CrossRef] [PubMed]